TITLE

First antipsychotic medication endorsed for children and teens

PUB. DATE
September 2007
SOURCE
Contemporary Pediatrics;Sep2007, Vol. 24 Issue 9, p23
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of risperidone by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adolescents ages 13 to 17 on August 22, 2007. The drug can also be used as a short-term treatment of manic or mixed episodes of bipolar I disorder in children and teens ages 10 to 17. According to Office of Pediatric Therapeutics Director Dianne Murphy, the pediatric studies of risperidone provided an opportunity to access the effectiveness, proper dose and safety of using the medication to treat children and adolescents.
ACCESSION #
26963331

 

Related Articles

  • Risperidone for irritability associated with autism.  // WHO Drug Information;2006, Vol. 20 Issue 4, p271 

    The article reports that risperidone orally disintegrating tablets have been approved by the U.S. Food and Drug Administration. The drug is an adult antipsychotic for the treatment of irritability in autistic children and adolescents. It is the first one to get the approval to treat behaviors...

  • Risperdal Consta update.  // MPR - Residents' Edition;Fall/Winter2009, Vol. 18 Issue 2, pA7 

    The article reports on the approval of the new monotherapy or adjuvant therapy Risperdal Consta from Janssen Pharmaceutica NV in the maintenance treatment of bipolar I disorder by the U.S. Food and Drug Administration (FDA). It mentions that the drug is a risperidone long-acting injection and it...

  • The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice. May, Meghan; Beauchemin, Megan; Vary, Calvin; Barlow, Deborah; Houseknecht, Karen L. // PLoS ONE;6/26/2019, Vol. 14 Issue 6, p1 

    Atypical antipsychotic medications such as risperidone are widely prescribed for diverse psychiatric indications including schizophrenia, bipolar disorder and depression. These medications have complex pharmacology and are associated with significant endocrine and metabolic side effects. This...

  • Latuda Approved for Bipolar Depression.  // Monthly Prescribing Reference;Aug2013, Vol. 29 Issue 8, pA18 

    The article informs that the U.S. Food and Drug Administration (FDA) has approved two new indications for the Latuda durg for the treatment of bipolar disorder.

  • Approval for Geodon.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports on the approval of Geodon capsules from Pfizer Inc. for the adjunctive maintenance treatment of bipolar I disorder in adults by the U.S. Food and Drug Administration (FDA).

  • Quetiapine.  // AHFS Consumer Medication Information;May2020, p1 

    Quetiapine tablets and extended-release (long-acting) tablets are used to treat the symptoms of schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions). Quetiapine tablets and extended-release tablets are also...

  • Cariprazine: First Global Approval. McCormack, Paul // Drugs;Nov2015, Vol. 75 Issue 17, p2035 

    Cariprazine (Vraylarâ„¢) is an oral atypical antipsychotic originated by Gedeon Richter. It is a potent dopamine D and D receptor partial agonist, which preferentially binds to the D receptor. Cariprazine also has partial agonist activity at serotonin 5-HT receptors. In September 2015,...

  • First Drug to Treat Irritability Associated With Autism.  // FDA Consumer;Jan/Feb2007, Vol. 41 Issue 1, p4 

    The article reports on the approval of Risperdal orally disintegrating tablets, an adult antipsychotic drug, for the symptomatic treatment of irritability in autistic children and adolescents by Food and Drug Administration (FDA) in the U.S. The approval is the first for the use of a drug to...

  • MYLAN RECEIVES FINAL FDA APPROVALS FOR GENERIC VERSIONS OF LAMICTAL TABLETS AND LAMICTAL CD.  // Psychiatry (1550-5952);Feb2009, Vol. 6 Issue 2, p14 

    The article reports that two subsidiaries of Mylan Inc. have received final approvals from the U.S. Food and Drug Administration (FDA) for their Abbreviated New Drug Applications (ANDAs) for lamotrigine tablets. The ANDAs were approved for the 25mg-200mg strengths of the generic version of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics